Tags

Type your tag names separated by a space and hit enter

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Int J Clin Pract. 2008 Jun; 62(6):925-31.IJ

Abstract

AIMS

Relationships were evaluated between treatment-related improvements in overactive bladder (OAB) symptoms as recorded in bladder diaries and patient-reported symptom bother, bladder-related problems and health-related quality of life (HRQL).

METHODS

A post hoc analysis was performed on data from patients with OAB (n = 863) enrolled in a 12-week open-label trial of tolterodine extended release (ER) in a primary care setting. At baseline and week 12, patients recorded every micturition, urgency episode and urgency urinary incontinence episode in 3-day bladder diaries. Patients also completed the Overactive Bladder Questionnaire (OAB-q) and Patient Perception of Bladder Condition (PPBC). Relationships between week 12 changes in bladder diary variables and OAB-q and PPBC scores were evaluated using Spearman correlations.

RESULTS

By week 12, tolterodine ER-related improvements in all bladder diary variables were significantly correlated with improvements on the PPBC (r = 0.26-0.36; p < 0.001), OAB-q Symptom Bother scale (r = 0.30-0.51; p < 0.001), and all OAB-q HRQL domains (r = -0.24 to -0.42; p < 0.001), although the correlations were generally small to moderate in size. Improvements on the PPBC were also significantly correlated with improvements on the OAB-q Symptom Bother scale (r = 0.63; p < 0.001) and all HRQL domains (r = -0.40 to -0.59; p < 0.001).

CONCLUSIONS

Tolterodine ER-related improvements in OAB symptoms (assessed by diary variables) and patients' perceptions of the changes in symptom bother, bladder-related problems and HRQL (assessed by PPBC and OAB-q) were significantly correlated. The OAB-q and the PPBC provide a relevant and important patient perspective for OAB treatment evaluation.

Authors+Show Affiliations

Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA. karin.coyne@unitedbiosource.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18479285

Citation

Coyne, K S., et al. "Relationships Between Improvements in Symptoms and Patient Assessments of Bladder Condition, Symptom Bother and Health-related Quality of Life in Patients With Overactive Bladder Treated With Tolterodine." International Journal of Clinical Practice, vol. 62, no. 6, 2008, pp. 925-31.
Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract. 2008;62(6):925-31.
Coyne, K. S., Elinoff, V., Gordon, D. A., Deng, D. Y., Brodsky, M., Glasser, D. B., Jumadilova, Z., & Carlsson, M. (2008). Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. International Journal of Clinical Practice, 62(6), 925-31. https://doi.org/10.1111/j.1742-1241.2008.01778.x
Coyne KS, et al. Relationships Between Improvements in Symptoms and Patient Assessments of Bladder Condition, Symptom Bother and Health-related Quality of Life in Patients With Overactive Bladder Treated With Tolterodine. Int J Clin Pract. 2008;62(6):925-31. PubMed PMID: 18479285.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. AU - Coyne,K S, AU - Elinoff,V, AU - Gordon,D A, AU - Deng,D Y, AU - Brodsky,M, AU - Glasser,D B, AU - Jumadilova,Z, AU - Carlsson,M, PY - 2008/5/16/pubmed PY - 2009/1/1/medline PY - 2008/5/16/entrez SP - 925 EP - 31 JF - International journal of clinical practice JO - Int J Clin Pract VL - 62 IS - 6 N2 - AIMS: Relationships were evaluated between treatment-related improvements in overactive bladder (OAB) symptoms as recorded in bladder diaries and patient-reported symptom bother, bladder-related problems and health-related quality of life (HRQL). METHODS: A post hoc analysis was performed on data from patients with OAB (n = 863) enrolled in a 12-week open-label trial of tolterodine extended release (ER) in a primary care setting. At baseline and week 12, patients recorded every micturition, urgency episode and urgency urinary incontinence episode in 3-day bladder diaries. Patients also completed the Overactive Bladder Questionnaire (OAB-q) and Patient Perception of Bladder Condition (PPBC). Relationships between week 12 changes in bladder diary variables and OAB-q and PPBC scores were evaluated using Spearman correlations. RESULTS: By week 12, tolterodine ER-related improvements in all bladder diary variables were significantly correlated with improvements on the PPBC (r = 0.26-0.36; p < 0.001), OAB-q Symptom Bother scale (r = 0.30-0.51; p < 0.001), and all OAB-q HRQL domains (r = -0.24 to -0.42; p < 0.001), although the correlations were generally small to moderate in size. Improvements on the PPBC were also significantly correlated with improvements on the OAB-q Symptom Bother scale (r = 0.63; p < 0.001) and all HRQL domains (r = -0.40 to -0.59; p < 0.001). CONCLUSIONS: Tolterodine ER-related improvements in OAB symptoms (assessed by diary variables) and patients' perceptions of the changes in symptom bother, bladder-related problems and HRQL (assessed by PPBC and OAB-q) were significantly correlated. The OAB-q and the PPBC provide a relevant and important patient perspective for OAB treatment evaluation. SN - 1742-1241 UR - https://www.unboundmedicine.com/medline/citation/18479285/Relationships_between_improvements_in_symptoms_and_patient_assessments_of_bladder_condition_symptom_bother_and_health_related_quality_of_life_in_patients_with_overactive_bladder_treated_with_tolterodine_ L2 - https://doi.org/10.1111/j.1742-1241.2008.01778.x DB - PRIME DP - Unbound Medicine ER -